BrightSpring Health Services, Inc.: insider trades · United States · SEC (Form 4)

About BrightSpring Health Services, Inc.

BrightSpring Health Services, Inc. (ticker BTSG) is a U.S.-based healthcare services company listed on the NASDAQ in the United States, focused on patients with complex needs who require coordinated care at home and in the community. The business has operating roots going back to 1974 through predecessor entities, but the company itself was incorporated in Delaware in 2017 as Phoenix Parent Holdings Inc. and later renamed BrightSpring Health Services, Inc. in May 2021. BrightSpring completed its IPO in January 2024, and its principal office is in Louisville, Kentucky. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1865782/000095017025055890/btsg-2025_ars.pdf)) From an industry standpoint, BrightSpring is positioned as an integrated home- and community-based healthcare platform that combines pharmacy capabilities with provider services. The company operates through two main segments: Pharmacy Solutions and Provider Services. Pharmacy Solutions includes specialty pharmacy, institutional pharmacy, and related medication-access services, while Provider Services covers home health, behavioral health, rehabilitation, hospice, and other community-based care offerings. This model allows BrightSpring to serve medically complex, chronically ill, and rare-disease populations across multiple care settings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1865782/000095017025055890/btsg-2025_ars.pdf)) Competitively, BrightSpring operates in a highly fragmented and competitive U.S. healthcare market, facing national, regional, and local rivals across pharmacy and provider services. Its strategic edge comes from scale, geographic density, clinical expertise, and the ability to connect medication management with direct patient care. Management also highlights intense competition in facility-based pharmacy, hospice, infusion, and specialty pharmacy markets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1865782/000095017025055890/btsg-2025_ars.pdf)) Key brands and capabilities include PharMerica and Onco360. In June 2025, Onco360 was selected as the national pharmacy partner for several newly approved therapies targeting advanced cancers and rare genetic disorders, underscoring BrightSpring’s positioning in high-complexity, high-touch specialty care niches where distribution, adherence support, and clinical coordination matter. ([ir.brightspringhealth.com](https://ir.brightspringhealth.com/news-releases/news-release-details/brightspring-health-services-announces-onco360r-selected/?utm_source=openai)) BrightSpring’s geographic footprint is national across the United States, with Louisville serving as its headquarters and operational hub. The company has also used tuck-in acquisitions to deepen market penetration and expand density in selected geographies. A major portfolio action came in 2025, when BrightSpring announced the divestiture of its Community Living business to Sevita for $835 million in cash; the transaction closed on March 30, 2026, allowing the company to further concentrate on its core pharmacy and provider platforms. ([ir.brightspringhealth.com](https://ir.brightspringhealth.com/news-releases/news-release-details/brightspring-health-services-inc-enters-definitive-agreement/?utm_source=openai)) Recent developments have reinforced the investment case. BrightSpring reported strong full-year 2025 results and entered 2026 with upgraded guidance after a solid first quarter, which featured robust revenue and adjusted EBITDA growth. For French-speaking investors, BTSG offers a healthcare equity tied to structural U.S. demand drivers such as population aging, expansion of home-based care, and rising need for specialized pharmacy and patient-support services. ([ir.brightspringhealth.com](https://ir.brightspringhealth.com/news-releases/news-release-details/brightspring-health-services-inc-reports-fourth-quarter-and-0?utm_source=openai))